Inhibiting HIV Infection Using Integrin Antagonists

Infection with HIV depletes and impairs CD4 cells, a key component of the immune system. Effective therapies such as highly active antiretroviral therapy (HAART) have focused on preserving CD4 cells. However, long term HAART has significant toxicity associated with it. The current technology describes the use of integrin antagonists as an alternative to treating or preventing HIV infection and replication. Specifically, alpha4 integrin plays a role in directing lymphocytes to the primary site of HIV replication. Inhibition of the interaction of alpha4beta1 or alpha4beta7 with gp120 can therefore be important in the development of effective HIV treatments.

Potential Commercial Applications: Competitive Advantages:
  • Inhibiting HIV infection
  • Inhibiting HIV replication

James Arthos (NIAID)
Diana Goode (NIAID)
Claudia Cicala (NIAID)
Anthony Fauci (NIAID)

Intellectual Property:
PCT Application No. PCT/US2007/086663
US Application No. 60/957,140
US Application No. 60/920,880
US Application No. 60/873,884
US Application No. 12/518,035

Collaboration Opportunity:

The NIAID Laboratory of Immunoregulation is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. James Arthos at 301-435-2374 for more information.

Licensing Contact:
Cristina Thalhammer-Reyero , Ph.D., M.B.A.
NIH Office of Technology Transfer
Phone: 301-435-4507

OTT Reference No: E-055-2007/0

Updated: Jun-10-2010